iShares Global Clean Energy ETF vs Revvity Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.22 (market cap $2.27B), while Revvity Inc trades at $154.66 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.5× iShares Global Clean Energy ETF's market cap, and Revvity Inc pays a 0.18% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Revvity Inc for 12 Days on average.
| ICLN | RVTY | |
|---|---|---|
Market Cap | $2.27B | $16.98B |
Volume | 6,845,064 | 1,456,900 |
52-Week High | $23.75 | $157.36 |
52-Week Low | $15.78 | $82.26 |
Typical Hold Time | 87 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.17, down 0.81% with bearish technical signals from moving averages. The ETF shows neutral momentum oscillators but faces significant volatility compared to traditional energy peers. Recent news highlights ICLN's 57.2% maximum drawdown and higher expense ratio of 0.38% versus fossil fuel ETFs, though geopolitical tensions are driving renewed interest in renewable energy infrastructure.
The clean energy sector faces competitive pressure from higher-yielding traditional energy ETFs, but long-term growth prospects remain supported by global energy transition trends. Key risks include expense ratio disadvantages and sector volatility, while potential catalysts include increased renewable adoption driven by geopolitical and environmental factors.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →